CytoMed Therapeutics Limited (GDTC)
NASDAQ:GDTC
Top Page
CytoMed Therapeutics Limited
(NASDAQ:GDTC)
Select Model
Select Model
Rating:44Neutral
Price Target:
$0.97
▼(-30.22% Downside)
Action:ReiteratedDate:04/09/26
The score is primarily constrained by weak financial performance driven by persistent losses and continued cash burn, despite some balance-sheet improvement. Technicals add additional caution as the stock trades below major moving averages with soft momentum. Valuation is difficult to support using P/E due to negative earnings, and no dividend yield data is available.
Positive Factors
Clinical-stage lead therapy
Regulatory clearance and an ongoing first-in-human trial materially de-risks the lead program versus preclinical peers. Over 2–6 months this supports development credibility, enables clinical data readouts and potential partnering or licensing milestones that strengthen long-term program value.
Negative Factors
Persistent cash burn
Consistent negative operating and free cash flow indicates ongoing cash burn that limits optionality. Without recurring positive cash generation, the company must rely on financing or asset sales, constraining its ability to sustain or scale clinical programs over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Clinical-stage lead therapy
Regulatory clearance and an ongoing first-in-human trial materially de-risks the lead program versus preclinical peers. Over 2–6 months this supports development credibility, enables clinical data readouts and potential partnering or licensing milestones that strengthen long-term program value.
Read all positive factors
CytoMed Therapeutics Limited (GDTC) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$11.83M
Dividend YieldN/A
Average Volume (3M)166.79K
Price to Earnings (P/E)―
Beta (1Y)0.18
Revenue GrowthN/A
EPS Growth-21.99%
CountryUS
Employees43
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding11,828,435
10 Day Avg. Volume104,297
30 Day Avg. Volume166,789
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.86
Enterprise Value/Revenue30.09
Enterprise Value/Gross Profit-42.05
Enterprise Value/Ebitda-3.07
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
CytoMed Therapeutics Limited Business Overview & Revenue Model
Company Description
CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers. The company's lead product candidate is CTM-N2D, which consists of expanded gamma de...
How the Company Makes Money
null...
CytoMed Therapeutics Limited Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
58
Neutral
Cash Flow
22
Negative
| Breakdown | Dec 2025 | Dec 2024 | Mar 2024 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 248.27K | 52.01K | 290.56K | 0.00 | 84.18K |
| Gross Profit | -689.55K | 52.38K | 381.92K | -81.03K | 81.59K |
| EBITDA | -3.34M | -1.79M | -2.94M | -1.10M | -1.05M |
| Net Income | -3.05M | -1.88M | -3.13M | -2.27M | -1.53M |
Balance Sheet | |||||
| Total Assets | 7.98M | 7.37M | 9.37M | 3.90M | 4.51M |
| Cash, Cash Equivalents and Short-Term Investments | 2.10M | 3.64M | 6.82M | 1.18M | 1.87M |
| Total Debt | 482.56K | 339.20K | 339.50K | 3.15M | 2.42M |
| Total Liabilities | 1.13M | 749.76K | 852.28K | 3.46M | 2.59M |
| Stockholders Equity | 6.54M | 6.57M | 8.52M | 438.24K | 1.92M |
Cash Flow | |||||
| Free Cash Flow | -4.40M | -3.01M | -2.72M | -1.40M | -1.70M |
| Operating Cash Flow | -3.70M | -1.98M | -2.68M | -1.04M | -1.27M |
| Investing Cash Flow | 929.28K | 494.59K | -2.11M | -353.37K | -610.72K |
| Financing Cash Flow | 208.65K | -33.36K | 8.16M | 793.25K | 3.09M |
CytoMed Therapeutics Limited Technical Analysis
Negative
1.39
Price Trends
1.02
Negative
1.27
Negative
1.66
Negative
Market Momentum
-0.01
Positive
44.58
Neutral
62.96
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GDTC, the sentiment is Negative. The current price of 1.39 is above the 20-day moving average (MA) of 1.04, above the 50-day MA of 1.02, and below the 200-day MA of 1.66, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 44.58 is Neutral, neither overbought nor oversold. The STOCH value of 62.96 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GDTC.
CytoMed Therapeutics Limited Risk Analysis
CytoMed Therapeutics Limited disclosed 106 risk factors in its most recent earnings report. CytoMed Therapeutics Limited reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
CytoMed Therapeutics Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $6.26M | -2.52 | -229.48% | ― | ― | 71.57% | |
46 Neutral | $29.80M | -0.82 | -87.18% | ― | ― | 38.42% | |
44 Neutral | $11.83M | -7.53 | -42.29% | ― | ― | -21.99% | |
42 Neutral | $4.39M | -0.56 | -68.21% | ― | ― | ― |
* Healthcare Sector Average
GDTC
CytoMed Therapeutics Limited
1.00
-1.74
-63.50%
AKTX
Akari Therapeutics
3.88
-43.72
-91.85%
MTVA
MetaVia
1.23
-13.95
-91.90%
PASG
Passage Bio
9.29
1.11
13.57%
KAPA
Kairos Pharma, Ltd.
0.58
-0.42
-41.90%
CytoMed Therapeutics Limited Corporate Events
CytoMed Therapeutics Widens 2025 Loss as It Accelerates Cell Therapy Trials and Southeast Asia Expansion
Mar 31, 2026
On March 31, 2026, CytoMed Therapeutics reported audited results for the year ended December 31, 2025, showing revenue and other operating income of US$780,857 and a wider net loss of US$3.11 million, driven partly by higher research, employee and...
CytoMed Therapeutics Refutes Misleading Claims, Confirms Ongoing First-in-Human Trial
Jan 28, 2026
On January 28, 2026, CytoMed Therapeutics issued a statement refuting what it described as inaccurate and misleading public claims about its research programs, clinical progress and operations, asserting that some of these assertions were taken ou...
CytoMed Therapeutics Outlines 2026 Clinical Plans and Seeks Shareholder Input on Patient-Access Scheme
Jan 13, 2026
On January 13, 2026, CytoMed Therapeutics issued a New Year update outlining its operational progress, financial runway, and strategic initiatives, including diversification into cord blood-derived natural killer cell therapies through its Longevi...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.